The frequency of B12 injections varies depending on the underlying cause of deficiency, the severity of symptoms, and whether neurological complications are present
With these players likely entering the market come 2028/2029, this adds pressure for Novo to act sooner rather than later
Individuals diagnosed with gastroparesis, bowel obstruction, NAION, pancreatitis, or other serious complications may pursue damages connected to hospitalization, surgery, long-term treatment, and ongoing medical care
However, emerging research has identified that GLP-1 receptors are not confined to the pancreas and gastrointestinal tract
A coda the diagnostics tag-along Theres one more bet, and it isnt pharma at all